Last reviewed · How we verify
BCG-Japan
At a glance
| Generic name | BCG-Japan |
|---|---|
| Also known as | Tokyo strain 172 |
| Sponsor | Bandim Health Project |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin (PHASE3)
- Diabetes Diagnosis, Management, Prevention and Education in Guinea-Bissau (PHASE4)
- Immunization With BCG Vaccine to Prevent Tuberculosis Infection (PHASE3)
- A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults. (PHASE2)
- BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine and Infant Mortality in Africa (PHASE4)
- A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD (PHASE2)
- Trial to Compare Two Strains of BCG (PHASE4)
- Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BCG-Japan CI brief — competitive landscape report
- BCG-Japan updates RSS · CI watch RSS
- Bandim Health Project portfolio CI